Are you currently facing long drug development cycles or difficulty in high-precision virus detection within complex clinical samples? Our HAV VP1 Specific Neutra™ Antibody Products help you develop highly specific diagnostics and therapeutic interventions through advanced recombinant DNA technology and high-affinity epitope mapping. Creative Biolabs provides the critical tools needed to neutralize viral infectivity and streamline your biopharmaceutical research.
The Hepatitis A Virus (HAV), a member of the Picornaviridae family, remains a significant global health challenge, causing acute liver inflammation and, in rare cases, fulminant hepatitis. The viral capsid is an icosahedral structure composed of 60 copies of three major structural proteins: VP1, VP2, and VP3. Among these, VP1 (Capsid Protein 1D) is recognized as the immunodominant surface protein and the primary target for neutralizing antibodies.
Structure and Function
VP1 is situated at the fivefold axes of the viral capsid. It possesses a characteristic beta-barrel "jelly roll" fold, which is common among picornaviruses. Unlike many other viruses in its family, HAV is found in two forms: a naked virion shed in feces and a quasi-enveloped form (eHAV) found in the blood. VP1 is essential for both forms, mediating interaction with the host cell receptor HAVCR1 (TIM-1). Research indicates that the N-terminus and specific loops of VP1 are critical for membrane penetration and the release of the viral RNA genome into the host cytoplasm.
Fig.1 HAV Structure and Genome.1
Molecular Interactions and Signaling Pathways
The HAV capsid protein VP1 is a critical structural component responsible for viral assembly and host cell entry. Beyond its structural role, VP1 modulates host signaling pathways to facilitate viral persistence and immune evasion. Specifically, VP1 interacts with the Host Cell Receptor 1 (HAVCR1/TIM-1), triggering downstream signaling that influences T-cell activation. Furthermore, VP1 is implicated in manipulating the Type I Interferon (IFN) signaling pathway, potentially suppressing the phosphorylation of STAT1/2 to blunt the innate antiviral response. These interactions allow the virus to bypass cellular defenses and maintain a favorable environment for replication within hepatocytes.
Clinical Impact and Disease
HAV infection typically follows a fecal-oral route. While often self-limiting in children, it can lead to severe jaundice, abdominal discomfort, and liver failure in older populations or those with underlying liver conditions. The VP1 protein is the focal point of the host's humoral immune response; the presence of anti-VP1 IgG generally confers lifelong immunity, making it a cornerstone for vaccine design and serological monitoring.
Neutralizing antibodies (NAbs) targeting the VP1 protein are indispensable in both clinical and laboratory settings. Their applications include:
Creative Biolabs offers a premium selection of HAV VP1 Specific Neutra™ antibodies, meticulously characterized for high-end research applications. Our products feature:
By choosing Creative Biolabs, you gain access to a sustainable supply of animal-free, recombinant antibodies that guarantee the reproducibility of your data across multi-year projects.
Creative Biolabs is dedicated to providing the biopharmaceutical industry with high-performance HAV VP1 Specific Neutra™ Antibody Products. Our solutions bridge the gap between basic virology and clinical application, offering the specificity and neutralization potency required to combat Hepatitis A. From early-stage drug discovery to the final stages of diagnostic validation, our team is here to support your scientific breakthroughs.
For detailed technical specifications, bulk pricing, or to discuss custom antibody engineering tailored to your project, please reach out to our specialist team.
Reference
Recombinant Anti-HAV VP1 Antibody (V3S-0522-YC3760) (CAT#: V3S-0522-YC3760)
Target: HAV VP1
Host Species: Human
Target Species: Hepatitis A Virus (HAV),
Application: ELISA,
Recombinant Anti-HAV VP1 Antibody (V3S-0522-YC3761) (CAT#: V3S-0522-YC3761)
Target: HAV VP1
Host Species: Human
Target Species: Hepatitis A Virus (HAV),
Application: ELISA,
Recombinant Anti-HAV VP1 Antibody (V3S-1022-YC3601) (CAT#: V3S-1022-YC3601)
Target: HAV VP1
Host Species: Mouse
Target Species: Hepatitis A virus (HAV),
Application: ELISA,Inhib,